In 50 adults with bipolar depression, three doses of intravenous scopolamine did not improve depressive symptoms (Hamilton scale) more than saline placebo; response, remission and functioning also did not differ. Mild dizziness and dry mouth were more common.
RCTn = 50
Miravalles et al. Antidepressant efficacy and safety of scopolamine in individuals with bipolar disorder (SCOPE-BD): A randomized double-blind placebo-controlled trial